 |
Section
1- Baxter's Motion for Entry of Permanent Injunction and Brief
in Support of Plaintiff's Motion for Permanent Injunction |
|
Section
2 - Cell Pro's Brief in Opposition to Plaintiff's Motion for Permanent
Injunction and in Support of Alternative Motion for Stay of Injunction
Pending Appeal |
|
Section
3 - CellPro Literature Describing CEPRATE System |
|
Section
4 - Summary Results from Published Studies Using the CEPRATE SC
Stem Cell Concentration System for Depletion of Tumor Cells in Peripheral
Blood and Bone Marrow |
|
Section
5 - Keith Ervin, Patent Litigation Threatens Cell-Therapy Progress,
Seattle Times, April 7, 1997 |
|
Section
6 - Summary of the Data Reported on Depletion of T-Cells from
Bone Marrow and Peripheral Blood after Selection with the CEPRATE
SC |
|
Section
7 - Investigator-Sponsored Studies Using the CEPRATE System |
|
Section
8 - CEPRATE SC Stem Cell Concentration System Bibliography |
|
Section
9 - Research Involving CEPRATE System Sponsored by NIH/NCI Funding |
|
Section
10 -Abstracts From the American Society of Hematology Meeting
in December 1996 |
|
Section
11 - Flake, et al., Brief Report: Treatment of X-Linked Severe
Combined Immunodeficiency by In Utero Transplantation of Paternal
Bone Marrow, New England Journal of Medicine (December 12,
1996) |
|
Section
12A - Transcript of Baxter Healthcare Corporation, et al. v. CellPro,
Inc., March 3, 1997 |
|
Section
12B -Transcript of Testimony of John Osth, President of Baxter's
Immunotherapy Division, Baxter Healthcare Corporation, et al. v. CellPro,
Inc., March 5, 1997 |
|
Section
13 - 1996 F.D.A. Office of Device Evaluation Annual Report |
|
Section
14 - Baxter Literature Describing the Isolex 300SA |
|
Section
15 - Civin et al., Highly Purified CD34 - Positive Cells
Reconstitute Hematopiesis, Journal of Clinical Oncology, Vol.
14, No. 8, August 1996 |
|
Section
16 -Baxter Literature Describing the Isolex 300i |
|
Section
17 - Boon Yap, Market Intelligence on Baxter Isolex 3000
SA and Isolex 300, (November 26, 1996) |
|
Section
18 - C. Chabannon, et al., High-Dose Chemotherapy Followed
by Reinfusion of Selected CD34+ Peripheral Blood Cells in Patients
with Poor Risk Breast Cancer |
|
Section
19 - Shelly Heimfeld, Additional Information on Baxter Randomized
Trial Described in ASH 1995 Abstract (March 20, 1997)(Two
Memoranda) |
|
Section
20 - Rich van den Broek, Will the Pain Ever End? H&Q Spot
Report (March 13, 1997) |
|
Section
21 - Facsimile from Kevin Davies, Lehman Brothers, to Richard
Murdoch, CellPro (February 25, 1007) |
